Eplerenone for the Treatment of Central Serous Chorioretinopathy

Inclusion Criteria: * Age 18 and over * Ability to give written informed consent * Sub-retinal fluid under fovea seen on OCT * Diagnosis of central serous chorioretinopathy (CSCR): classification is at the discretion of the investigator, but general guidelines are 1. Acute- first episode or symptoms less than one month prior to presentation 2. Chronic- previously documented sub-foveal fluid, any prior treatment, symptoms for over 3 months, or \<50% reduction in fluid thickness on OCT after 3 months. Exclusion Criteria: * Age under 18 * Impaired decision-making ability * At initial laboratory screening serum potassium \>5.5 milliequivalent (mEq)/L * At initial laboratory screening serum creatinine \>2 mg/dL in men and \>1.8 mg/dL in women or decreased renal function by creatinine clearance less than 50 mL/min * Absence of sub-foveal fluid * Any patient with prior treatment for CSCR within 3 months of enrollment * Patients taking potassium supplements or potassium-sparing diuretics spironolactone, amiloride, and triamterene and/or potent CYP3A4 (cytochrome) inhibitors (amifostine, cyclosporine, fluconazole, itraconazole, ketoconazole, mifepristone, posaconazole, potassium salts, rituximab, tacrolimus, voriconazole nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir) * Women who are pregnant or are actively trying to conceive * Patients with type 1 or type 2 diabetes